OncoGenex Pharmaceuticals Downgraded by RBC Capital to “Sector Perform” (OGXI)
OncoGenex Pharmaceuticals (NASDAQ:OGXI) was downgraded by investment analysts at RBC Capital from an “outperform” rating to a “sector perform” rating in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. They currently have a $4.50 target price on the stock, down from their previous target price of $19.00. RBC Capital’s price objective points to a potential upside of 14.80% from the stock’s previous close.
OGXI has been the subject of a number of other recent research reports. Analysts at Needham & Company LLC downgraded shares of OncoGenex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. They now have a $14.00 price target on the stock, down previously from $30.00. Analysts at CRT Capital initiated coverage on shares of OncoGenex Pharmaceuticals in a research note on Thursday, February 27th. They set a “buy” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $12.70.
Shares of OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded up 1.82% on Tuesday, hitting $3.92. 1,439,080 shares of the company’s stock traded hands. OncoGenex Pharmaceuticals has a 52 week low of $3.82 and a 52 week high of $14.25. The stock has a 50-day moving average of $10.82 and a 200-day moving average of $9.59. The company’s market cap is $57.7 million.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.21. The company had revenue of $8.60 million for the quarter, compared to the consensus estimate of $10.20 million. Analysts expect that OncoGenex Pharmaceuticals will post $-1.33 EPS for the current fiscal year.
OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.